EGFR and neoplasm: We also demonstrated that pre-decoration of Doxisome with PEG engagerEGFR could enhance the half-life of the engagers and improve the therapeutic index of Doxisome treatment against EGFR+ human tumour xenografts, indicating that both pre-mixing and pre-targeting of PEG engagers are promising therapeutic approaches.